Alison Axtman

Alison Axtman

SGC UNC

Axtman

Alison Axtman

(216) 470-7201

Biography

Alison Axtman is a synthetic medicinal chemist with more than 10 years of research experience working at the interface of chemical and biology. Alison earned her PhD in Medicinal Chemistry at the University of Kansas, and carried out her post-doctoral training in the Department of Chemistry at Stanford University. Alison’s research has focused on the synthesis of small molecules that selectively modulate proteins implicated in disease-propagating pathways. As a member of the GSK Chemical Biology department, she led a program to understand the molecular basis of immune modulation by a class of natural products and developed analogs with improved drug properties. Alison is currently a Research Assistant Professor in the Chemical Biology and Medicinal Chemistry Department in the UNC Eshelman School of Pharmacy. At the SGC-UNC, she leads the design of novel chemical probes for understudied protein kinases that will be openly shared with collaborators to facilitate target discovery in human disease-relevant assays. When she’s not in the lab, Alison can be most often found at the gym preparing for the next CrossFit or GRID competition with her teammates.

2022

Use of AD Informer Set compounds to explore validity of novel targets in Alzheimer's disease pathology.

Potjewyd FM, Annor-Gyamfi JK, Aubé J, Chu S, Conlon IL, Frankowski KJ, Guduru SKR, Hardy BP, Hopkins MD, Kinoshita C, Kireev DB, Mason ER, Moerk CT, Nwogbo F, Pearce KH, Richardson TI, Rogers DA, Soni DM, Stashko M, Wang X, Wells C, Willson TM, Frye SV, Young JE, Axtman AD

Alzheimers Dement (N Y). 2022-4-19 . 8(1):e12253 .doi: 10.1002/trc2.12253

PMID: 35434254

2021

Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration.

Drewry DH, Annor-Gyamfi JK, Wells CI, Pickett JE, Dederer V, Preuss F, Mathea S, Axtman AD

J Med Chem. 2021-8-1 . .doi: 10.1021/acs.jmedchem.1c00440

PMID: 34333981

Development of a potent and selective chemical probe for the pleiotropic kinase CK2.

Wells CI, Drewry DH, Pickett JE, Tjaden A, Krämer A, Müller S, Gyenis L, Menyhart D, Litchfield DW, Knapp S, Axtman AD

Cell Chem Biol. 2021-1-11 . .doi: 10.1016/j.chembiol.2020.12.013

PMID: 33484635

The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification.

Wells CI, Al-Ali H, Andrews DM, Asquith CRM, Axtman AD, Dikic I, Ebner D, Ettmayer P, Fischer C, Frederiksen M, Futrell RE, Gray NS, Hatch SB, Knapp S, Lücking U, Michaelides M, Mills CE, Müller S, Owen D, Picado A, Saikatendu KS, Schröder M, Stolz A, Tellechea M, Turunen BJ, Vilar S, Wang J, Zuercher WJ, Willson TM, Drewry DH

Int J Mol Sci. 2021-1-8 . 22(2): .doi: 10.3390/ijms22020566

PMID: 33429995

Towards a RIOK2 chemical probe: cellular potency improvement of a selective 2-(acylamino)pyridine series.

Wang CB, Lorente-Macías Á, Wells C, Pickett JE, Picado A, Zuercher WJ, Axtman AD

RSC Med Chem. 2021-1-1 . 12(1):129-136 .doi: 10.1039/d0md00292e

PMID: 34046605

2020

PKIS deep dive yields a chemical starting point for dark kinases and a cell active BRSK2 inhibitor.

Tamir TY, Drewry DH, Wells C, Major MB, Axtman AD

Sci Rep. 2020-9-28 . 10(1):15826 .doi: 10.1038/s41598-020-72869-9

PMID: 32985588

NeuroChat with Research Assistant Professor Alison Axtman.

Lindsley CW, Axtman AD

ACS Chem Neurosci. 2020-9-16 . 11(18):2783-2785 .doi: 10.1021/acschemneuro.0c00548

PMID: 32933260